TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29746639

Group type: COMPARATOR
Intervention: BCAA diet (1.03 g · kg-1 · d-1)
Number of subjects: 5

Group type: COMPARATOR
Intervention: EAA diet (1.23 g · kg-1 · d-1)
Number of subjects: 5

Group type: COMPARATOR
Intervention: SUF diet (1.75 g · kg-1 · d-1)
Number of subjects: 5

Group type: COMPARATOR
Intervention: NEAA diet (1.75 g · kg-1 · d-1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: BASE diet (0.8 g · kg-1 · d-1)
Number of subjects: 5
Study: 29746650

Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement
Number of subjects: 351
Study: 29747074

Group type: EXPERIMENTAL
Intervention: 150 mg/day of zinc from day +5 to day +100 after transplant
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard antimicrobial prophylaxis
Number of subjects: 18
Study: 29747644

Group type: EXPERIMENTAL
Intervention: EHR-based tools for insurance assistance
Number of subjects: 15024
Study: 29747670

Group type: EXPERIMENTAL
Intervention: Jiedu Tongluo granules (JDTLG) with conventional treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo with conventional treatment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Jiedu Tongluo granules (JDTLG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Jiedu Tongluo granules (JDTLG) and placebo
Number of subjects: 80
Study: 29747700

Group type: EXPERIMENTAL
Intervention: Myo-inositol (2 g, twice per day) for three months followed by myo-inositol plus alpha-lactalbumin (50 mg, twice per day) for three months
Number of subjects: 37

Group type: COMPARATOR
Intervention: Myo-inositol (2 g, twice per day) for three months
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Myo-inositol plus alpha-lactalbumin (50 mg, twice per day)
Number of subjects: 37
Study: 29747838

Group type: EXPERIMENTAL
Intervention: High-Dose Ferric Carboxymaltose
Number of subjects: 0
Study: 29747915

Group type: EXPERIMENTAL
Intervention: Third universal definition of PCI-related myocardial infarction (MI)
Number of subjects: 13038

Group type: EXPERIMENTAL
Intervention: SCAI criteria for PCI-related MI
Number of subjects: 13038

Group type: COMPARATOR
Intervention: Local investigator detection of angiographic complications
Number of subjects: 13038
Study: 29748148

Group type: EXPERIMENTAL
Intervention: LPL-FCS individuals
Number of subjects: 52

Group type: COMPARATOR
Intervention: non-LPL-FCS individuals
Number of subjects: 52
Study: 29748160

Group type: EXPERIMENTAL
Intervention: Activity tracking using Fitbit Alta HR and a mobile phone app designed for the study.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Activity tracking with weekly review of self-reports and activity information.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Activity tracking and self-reporting with weekly review.
Number of subjects: 50
Study: 29748219

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1278
Study: 29748344

Group type: EXPERIMENTAL
Intervention: Data collection and abstraction of patient characteristics, diagnostic testing, treatments, and in-hospital outcomes.
Number of subjects: 10000
Study: 29748435

Group type: EXPERIMENTAL
Intervention: End-of-treatment PET (negative Deauville 1-3)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: End-of-treatment PET (positive Deauville 4-5)
Number of subjects: 93
Study: 29748443

Group type: EXPERIMENTAL
Intervention: coltuximab ravtansine
Number of subjects: 61
Study: 29748444

Group type: EXPERIMENTAL
Intervention: Bendamustine (90 mg/m²) plus Rituximab
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 100
Study: 29748602

Group type: EXPERIMENTAL
Intervention: Neoadjuvant clinical trials (NCT02876107 and NCT03101748)
Number of subjects: 0
Study: 29748650

Group type: EXPERIMENTAL
Intervention: Vegan medical professionals
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Vegetarian medical professionals
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Omnivore medical professionals
Number of subjects: 198

Group type: COMPARATOR
Intervention: Omnivores
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Vegans and vegetarians
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Vegans
Number of subjects: 198
Study: 29748847

Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg twice daily (BID)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg BID
Number of subjects: 225
Study: 29749274

Group type: EXPERIMENTAL
Intervention: Cycle-tracking apps
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Standard days method
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Rhythm method
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Alternative rhythm method
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Simple calendar method
Number of subjects: 949
Study: 29749279

Group type: EXPERIMENTAL
Intervention: Radioligands for imaging TSPO
Number of subjects: 0
Study: 29749403

Group type: EXPERIMENTAL
Intervention: Obinutuzumab-bendamustine (G-B)
Number of subjects: 158
Study: 29749945

Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP) only
Number of subjects: 1670

Group type: COMPARATOR
Intervention: At least 1 shock
Number of subjects: 1670

Group type: COMPARATOR
Intervention: ATP only
Number of subjects: 1670

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 1670
Study: 29750067

Group type: EXPERIMENTAL
Intervention: Non-vitamin-K-antagonist oral anticoagulant (NOAC) treatment
Number of subjects: 37439

Group type: COMPARATOR
Intervention: Vitamin-K-antagonist (VKA) treatment
Number of subjects: 37439
Study: 29750396

Group type: EXPERIMENTAL
Intervention: Cabazitaxel at a starting dose of 20 mg/m², escalated to a maximum tolerated dose (MTD) of 30 mg/m².
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cabazitaxel at a dose of 35 mg/m².
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (general safety profile).
Number of subjects: 23
Study: 29750416

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Highest quartile of 25(OH)D
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: CYP2R1 rs12794714
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: C10orf88 rs6599638
Number of subjects: 419
Study: 29750698

Group type: EXPERIMENTAL
Intervention: Immediate postoperative copeptin concentrations (0 h)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Postoperative copeptin concentrations
Number of subjects: 30
Study: 29750699

Group type: EXPERIMENTAL
Intervention: Closed-loop-assisted goal-directed fluid therapy (GDFT) with a baseline crystalloid infusion of 3 ml/kg/h and additional 100 ml fluid boluses of crystalloid or colloid.
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Closed-loop-assisted goal-directed fluid therapy (GDFT)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Historical control group (non-GDFT patients)
Number of subjects: 208
Study: 29750747

Group type: EXPERIMENTAL
Intervention: Clofarabine at a dose of 50 mg/m/d for 5 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clofarabine
Number of subjects: 15
Study: 29750766

Group type: EXPERIMENTAL
Intervention: Formula-fed infants
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Maternal education <12 years
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Maternal viral load >1,000,000 copies/mL at delivery
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Overall infant mortality rate
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Infant mortality rate in Brazil
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Infant mortality rate in South Africa
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Undernutrition and stunting at 1 month of age
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Infant mortality likelihood in South Africa vs Brazil
Number of subjects: 1000

Group type: COMPARATOR
Intervention: High maternal viral load
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Birth weight-for-age Z score ≤-2
Number of subjects: 1000
Study: 29750955

Group type: EXPERIMENTAL
Intervention: Myomectomy (46% of all procedures, with laparoscopic or robotic myomectomy comprising 19% of all procedures)
Number of subjects: 2031

Group type: EXPERIMENTAL
Intervention: Hysterectomy (38% of all procedures)
Number of subjects: 2031
Study: 29750983

Group type: EXPERIMENTAL
Intervention: SIC-8000
Number of subjects: 211

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 211
Study: 29751110

Group type: EXPERIMENTAL
Intervention: EEG reactivity to eye opening in patients who later developed pain
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: EEG reactivity to eye opening in patients with existing pain
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Alpha band power at BA7 in patients with or later developing pain
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dominant alpha frequency and beta band power at BA7 in all SCI groups
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: EEG reactivity to eye opening and reduced spontaneous and induced alpha activity over the parietal cortex
Number of subjects: 41
Study: 29751154

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional therapies
Number of subjects: 90
Study: 29751168

Group type: EXPERIMENTAL
Intervention: Hoarding Disorder (HD) group
Number of subjects: 83

Group type: COMPARATOR
Intervention: Healthy Control (HC) group
Number of subjects: 83
Study: 29751507

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation pre-RT
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation post-RT
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo post-RT
Number of subjects: 70
Study: 29751792

Group type: EXPERIMENTAL
Intervention: gemcitabine-based chemotherapy
Number of subjects: 6
Study: 29751980

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29752199

Group type: EXPERIMENTAL
Intervention: R-GemOx regimen (rituximab 375 mg/m2, gemcitabine, and oxaliplatin) administered intravenously as first-line treatment.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: R-GemOx regimen (rituximab 375 mg/m2, gemcitabine, and oxaliplatin) administered intravenously.
Number of subjects: 60
Study: 29752388

Group type: EXPERIMENTAL
Intervention: PCI plus optimal medical therapy (OMT)
Number of subjects: 2287

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 2287
Study: 29753353

Group type: EXPERIMENTAL
Intervention: ICT-facilitated care (TC)
Number of subjects: 1406
Study: 29753517

Group type: EXPERIMENTAL
Intervention: Liberal fluids approach (50 to 75 mL/kg during the first 6 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Restrictive fluids approach (≤30 mL/kg)
Number of subjects: 0
Study: 29753544

Group type: EXPERIMENTAL
Intervention: Late diagnosis (diagnosis at or after age 13 years)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Early diagnosis (diagnosis before age 13 years)
Number of subjects: 110
Study: 29753733

Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CTA)
Number of subjects: 440
Study: 29754400

Group type: EXPERIMENTAL
Intervention: Nonadherence to physical activity
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Nonadherence to sun protection
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Nonadherence to diet recommendations
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Nonadherence to alcohol consumption guidelines
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Nonadherence to smoking cessation
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Nonadherence to follow-up visits
Number of subjects: 1397
Study: 29754500

Group type: EXPERIMENTAL
Intervention: Rare primary headaches (Chapter 3 and Chapter 4 of the International Classification of Headache Disorders 3rd edition)
Number of subjects: 20883

Group type: EXPERIMENTAL
Intervention: Cluster headaches (most frequently diagnosed rare headaches)
Number of subjects: 20883
Study: 29754661

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 2200

Group type: COMPARATOR
Intervention: State-of-the-art rate or rhythm control drug therapy
Number of subjects: 2200
Study: 29754670

Group type: EXPERIMENTAL
Intervention: PACT-HF transitional care model including self-care education, multidisciplinary care, early follow-up, post-discharge nurse-led home visits, and outpatient care in Heart Function clinics.
Number of subjects: 3200
Study: 29755397

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study: 29755591

Group type: EXPERIMENTAL
Intervention: Turnip rapeseed oil
Number of subjects: 37

Group type: COMPARATOR
Intervention: Butter
Number of subjects: 37
Study: 29755707

Group type: EXPERIMENTAL
Intervention: Oral colistin for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 0
Study: 29756206

Group type: EXPERIMENTAL
Intervention: Oral pimasertib (once daily for 5 days on/2 days off or twice daily continuously) combined with weekly gemcitabine (1,000 mg/m2)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Oral pimasertib
Number of subjects: 53

Group type: COMPARATOR
Intervention: Weekly gemcitabine (1,000 mg/m2)
Number of subjects: 53
Study: 29756211

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) for appropriate candidates
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) for uncertain candidates
Number of subjects: 471

Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) for inappropriate candidates
Number of subjects: 471
Study: 29756531

Group type: EXPERIMENTAL
Intervention: Pediatric Malaria Vaccine (GSK/PATH-MVI RTS,S)
Number of subjects: 52
Study: 29756750

Group type: EXPERIMENTAL
Intervention: Remifentanil IV infusion of 0.005 µg/kg/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil IV infusion of 0.05 µg/kg/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil IV infusion of 0.1 µg/kg/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil IV infusion of 0.15 µg/kg/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NOL monitoring
Number of subjects: 40
Study: 29757399

Group type: EXPERIMENTAL
Intervention: DHEAS ≥40 µg/dL
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: DHEAS
Number of subjects: 432
Study: 29758112

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel therapies targeting FXR, TGR5, PPAR, PXR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29758172

Group type: EXPERIMENTAL
Intervention: E-consent process
Number of subjects: 86
Study: 29758405

Group type: EXPERIMENTAL
Intervention: AV algorithm pacing
Number of subjects: 64

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 64
Study: 29759075

Group type: EXPERIMENTAL
Intervention: CAP patients (non-severe and severe)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Metabolite panel (lactate, sphinganine, DHEA-S)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 175
Study: 29759110

Group type: EXPERIMENTAL
Intervention: Nutritional telemonitoring, nutrition education, and follow-up by a nurse for 6 months
Number of subjects: 214
Study: 29759500

Group type: EXPERIMENTAL
Intervention: TYRX Antibacterial Envelope
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: TYRX Antibacterial Envelope (CRT cohort)
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: TYRX Antibacterial Envelope (ICD group)
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Control (site-matched and comorbidity-matched)
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Control (published benchmark)
Number of subjects: 1129
Study: 29759576

Group type: EXPERIMENTAL
Intervention: Period of <3 years since MI (lowest quartile, n = 172)
Number of subjects: 693

Group type: COMPARATOR
Intervention: Period of ≥3 years since MI (n = 521)
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Patients with LBBB and period of ≥3 years since MI
Number of subjects: 693
Study: 29759606

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 192
Study: 29759618

Group type: EXPERIMENTAL
Intervention: Medtronic MRI-conditional pacing system
Number of subjects: 2629
Study: 29759624

Group type: EXPERIMENTAL
Intervention: Long detection programming (30 of 40 intervals)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Standard programming (18 of 24 intervals)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Long detection programming
Number of subjects: 545
Study: 29759747

Group type: EXPERIMENTAL
Intervention: Catheter stability with CF applied ≥73% of the time within the preselected CF range
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average CF categories of 0 to 10 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average CF categories of 10 to 20 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average CF categories of >20 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CF of 6.5 to 10.3 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PV gaps exceeding 10.6-mm distance
Number of subjects: 0
Study: 29759834

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Frailty (defined as G8 score <14)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: G8 score <10.25
Number of subjects: 151
Study: 29759838

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 72-h Holter monitoring
Number of subjects: 82
Study: 29759864

Group type: EXPERIMENTAL
Intervention: ICD or CRT-D in black patients
Number of subjects: 1777

Group type: COMPARATOR
Intervention: ICD or CRT-D in white patients
Number of subjects: 1777
Study: 29759903

Group type: EXPERIMENTAL
Intervention: Prophylaxis for digestive disorders with omeprazole
Number of subjects: 419

Group type: COMPARATOR
Intervention: No prophylaxis with omeprazole (Control)
Number of subjects: 419
Study: 29759953

Group type: EXPERIMENTAL
Intervention: Life in a Day mobile phone app
Number of subjects: 40
Study: 29759957

Group type: EXPERIMENTAL
Intervention: MORPH intervention (12-week duration)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 30
Study: 29760012

Group type: EXPERIMENTAL
Intervention: Core laboratory scores for ASPECTS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Core laboratory scores for ECASS HT classification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Core laboratory scores for TICI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dichotomized TICI score (TICI 0/1/2a vs 2b/3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI-based scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT-based scores
Number of subjects: 0
Study: 29760162

Group type: EXPERIMENTAL
Intervention: Unrelated cord blood transplantation (CBT)
Number of subjects: 26
Study: 29760228

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo or standard care not specified)
Number of subjects: 0
Study: 29760559

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 4110

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 4110

Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 4110
Study: 29760737

Group type: EXPERIMENTAL
Intervention: ADRC-enriched fat grafting (group I)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Centrifuged autologous fat (CAF) grafts (group II)
Number of subjects: 14
Study: 29760763

Group type: EXPERIMENTAL
Intervention: Vortioxetine (5, 10, or 20 mg)
Number of subjects: 27
Study: 29761174

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) 50 mg/100 mg once daily for 12 weeks
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR)
Number of subjects: 337
Study: 29761420

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib or MTX with CDAI remission or low disease activity (LDA) at month 6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 0
Study: 29761785

Group type: EXPERIMENTAL
Intervention: cardiac glycoside reductase
Number of subjects: 0
Study: 29761903

Group type: EXPERIMENTAL
Intervention: Combination of ABC294640 (sphingosine kinase 2 inhibitor) and ABT-199 (Bcl-2 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABT-199 (Bcl-2 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABC294640 (sphingosine kinase 2 inhibitor)
Number of subjects: 0
Study: 29762444

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma injection
Number of subjects: 17
Study: 29762532

Group type: EXPERIMENTAL
Intervention: Trimester-specific air pollution exposure (divided into quartiles Q1⁻4)
Number of subjects: 0
Study: 29762717

Group type: EXPERIMENTAL
Intervention: Toca 511 + Toca FC
Number of subjects: 56
Study: 29762769

Group type: EXPERIMENTAL
Intervention: Surgical treatment for traumatic ASDH in younger patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment for traumatic ASDH in elderly patients (≥70 yr)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment for traumatic ASDH in both younger and elderly patients
Number of subjects: 0
Study: 29763980

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) group (N=40)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (N=31)
Number of subjects: 71
Study: 29764238

Group type: EXPERIMENTAL
Intervention: BI 695501 via autoinjector (AI)
Number of subjects: 77
Study: 29764386

Group type: EXPERIMENTAL
Intervention: Detailed clinical examination by a movement disorder specialist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) biomarkers
Number of subjects: 0
Study: 29764550

Group type: EXPERIMENTAL
Intervention: Fluid challenge
Number of subjects: 40
Study: 29764716

Group type: EXPERIMENTAL
Intervention: Individualized-Targeted Computerized Cognitive Training
Number of subjects: 0
Study: 29764869

Group type: EXPERIMENTAL
Intervention: Tele-UPCAT (AOT at home for 3 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care (control group for 3 weeks)
Number of subjects: 24